Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Ertugliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), is approved in the US, EU, and other regions for the treatment of adults with type 2 diabetes mellitus (T2DM). This review summarizes the ertugliflozin pharmacokinetic (PK) and pharmacodynamic data obtained during phase...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Clin Pharmacokinet
Autori principali: Fediuk, Daryl J., Nucci, Gianluca, Dawra, Vikas Kumar, Cutler, David L., Amin, Neeta B., Terra, Steven G., Boyd, Rebecca A., Krishna, Rajesh, Sahasrabudhe, Vaishali
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2020
Soggetti:
Review Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7403171/
https://ncbi.nlm.nih.gov/pubmed/32337660
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-020-00875-1
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi